T
MRNA icon

TCWP’s Moderna MRNA Stock Holding History

TCWP’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-651
Closed -$112K – 1173
2022
Q1 		$112K Buy
+651
New +$110K 0.02% 331

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TCWP's MRNA Position: Q2 2022 in Review

TCWP sold out of Moderna (MRNA) in Q2 2022, closing a stake of 651 shares — an estimated $112K sold.

TCWP first reported a position in MRNA in Q1 2022 and held it in 1 quarter. The position peaked at $112K in Q1 2022. 981 funds tracked by Wall St. Rank hold MRNA as of Q2 2022.

  • TCWP reported no remaining Moderna position as of Q2 2022 after selling out during the quarter.
  • TCWP sold 651 Moderna shares in Q2 2022, an estimated $112K.
  • TCWP first reported a position in Moderna in Q1 2022 and held it in 1 quarter.
  • TCWP's Moderna position peaked at $112K in Q1 2022.
  • 981 funds tracked by Wall St. Rank held Moderna as of Q2 2022.

Based on TCWP's 13F filing for Q2 2022, filed 15 Aug 2022.